Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.06 USD | +1.47% | +1.48% | -34.19% |
Mar. 28 | Arcadia Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 28 | Transcript : Arcadia Biosciences, Inc., Q4 2023 Earnings Call, Mar 28, 2024 |
Financials (USD)
Sales 2024 * | 6.22M | Sales 2025 * | 8M | Capitalization | 2.81M |
---|---|---|---|---|---|
Net income 2024 * | -10M | Net income 2025 * | -8M | EV / Sales 2024 * | 0.45 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 0.35 x |
P/E ratio 2024 * |
-0.37
x | P/E ratio 2025 * |
-0.45
x | Employees | 21 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.4% |
Latest transcript on Arcadia Biosciences, Inc.
1 day | +1.47% | ||
1 week | +1.48% | ||
Current month | -6.79% | ||
1 month | -8.44% | ||
3 months | -17.60% | ||
6 months | -36.62% | ||
Current year | -34.19% |
Managers | Title | Age | Since |
---|---|---|---|
Stanley Jacot
CEO | Chief Executive Officer | 54 | 22-02-01 |
Thomas Schaefer
DFI | Director of Finance/CFO | 48 | 20-06-30 |
Kevin Comcowich
CHM | Chairman | 55 | 16-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Amy Yoder
BRD | Director/Board Member | 56 | 17-08-09 |
Gregory Waller
BRD | Director/Board Member | 74 | 17-06-12 |
Kevin Comcowich
CHM | Chairman | 55 | 16-10-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-24 | 2.06 | +1.47% | 19,747 |
24-04-23 | 2.03 | -4.24% | 6,783 |
24-04-22 | 2.12 | +2.91% | 65,795 |
24-04-19 | 2.06 | +5.64% | 13,564 |
24-04-18 | 1.95 | -3.93% | 17,324 |
Delayed Quote Nasdaq, April 24, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-34.19% | 2.81M | |
+14.29% | 38.28B | |
-.--% | 11.12B | |
-7.38% | 7.29B | |
+6.02% | 6.83B | |
-2.92% | 6.02B | |
-5.07% | 5.61B | |
-10.39% | 5.52B | |
+29.87% | 5.13B | |
-14.30% | 4.49B |
- Stock Market
- Equities
- RKDA Stock